Yoav Michowitz

Yoav Michowitz

Auto-generated profile, based on publicly available information

Yoav Michowitz

Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel; Hadassah Hebrew University, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in European Heart Journal
Verified
Journal Article
Closed access
YMYoav Michowitz
Yoav Michowitz
MKMads Brix Kronborg
Mads Brix Kronborg
MGMichael Glikson
Michael Glikson
JNJens Cosedis Nielsen
Jens Cosedis Nielsen

28 March 2025 in EP Europace
Verified
Journal Article
Open access
MGMichael Glikson
Michael Glikson
HBHaran Burri
Haran Burri
AAAmr Abdin
Amr Abdin
ÓCÓscar Cano
Óscar Cano
KCkarol curila
karol curila
NVNiraj Varma
Niraj Varma
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing. Since the 2021 European Society of Cardiology pacing guidelines, there has been growing evidence that this therapy is safe and effective. Furthermore, left bundle branch area pacing was not covered in these guidelines due to limited evidence at that time. This Clinical Consensus Statement provides advice on indications for CSP, taking into account the significant evolution in this domain.

2 August 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
NVNiraj Varma
Niraj Varma
FBFrieder Braunschweig
Frieder Braunschweig
HBHaran Burri
Haran Burri
GHGerhard Hindricks
Gerhard Hindricks
Dominik LinzDominik Linz
Dominik Linz
JNJens Cosedis Nielsen
Jens Cosedis Nielsen
This reviews the transition of remote monitoring of patients with cardiac electronic implantable devices from curiosity to standard of care. This has been delivered by technology evolution from patient-activated remote interrogations at appointed intervals to continuous monitoring that automatically flags clinically actionable information to the clinic for review. This model has facilitated follow-up and received professional society recommendations. Additionally, continuous monitoring has provided a new level of granularity of diagnostic data enabling extension of patient management from device to disease management. This ushers in an era of digital medicine with wider applications in cardiovascular medicine.

1 January 2014 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SBSimon Biner
Simon Biner
YMYoav Michowitz
Yoav Michowitz
Eran LeshemEran Leshem
Eran Leshem
YTYan Topilsky
Yan Topilsky
EBEyal Ben-Assa
Eyal Ben-Assa
AFAriel Finkelstein
Ariel Finkelstein

17 December 2016 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
OTOholi Tovia-Brodie
Oholi Tovia-Brodie
YBYael Ben-Haim
Yael Ben-Haim
EJErel Joffe
Erel Joffe
AFAriel Finkelstein
Ariel Finkelstein
AGAharon Glick
Aharon Glick
YMYoav Michowitz
Yoav Michowitz

19 January 2011 in EP Europace
Verified
Journal Article
Open access
PDF file
YMYoav Michowitz
Yoav Michowitz
NLNicolas Lellouche
Nicolas Lellouche
TCTahmeed Contractor
Tahmeed Contractor
TBTara Bourke
Tara Bourke
IWIsaac Wiener
Isaac Wiener
KSKalyanam Shivkumar
Kalyanam Shivkumar
The utility of defibrillation threshold testing in patients undergoing implantable cardioverter–defibrillator (ICD) implantation is controversial. Higher defibrillation thresholds have been noted in patients undergoing implantation of cardiac resynchronization therapy defibrillators (CRT-D). Since the risks and potential benefits of testing may be higher in this population, we sought to assess the impact of defibrillation safety margin or vulnerability safety margin testing in CRT-D recipients. A total of 256 consecutive subjects who underwent CRT-D implantation between January 2003 and December 2007 were retrospectively reviewed. Subjects were divided into two groups based on whether (n= 204) or not (n= 52) safety margin testing was performed. Patient characteristics, tachyarrhythmia therapies, procedural results, and clinical outcomes were recorded. Baseline characteristics, including heart failure (HF) severity, were comparable between the groups. Four cases of HF exacerbation (2%), including one leading to one death, were recorded in the tested group immediately post-implantation. No complications were observed in the untested group. After a mean follow-up of 32 ± 20 months, the proportion of appropriate shocks in the two groups was similar (31 vs. 25%, P = 0.49). There were three cases of failed appropriate shocks in the tested group, despite adequate safety margins at implantation, whereas no failed shocks were noted in the untested group. Survival was similar in the two groups. Defibrillation efficacy testing during implant of CRT-D was associated with increased morbidity and did not predict the success of future device therapy or improve survival during long-term follow-up.